.jpg)
Get precise autoimmune disease detection with the HLA-B27 (Flow Cytometry) test at Diagnopein, Karad. Trusted accuracy, latest technology, and expert diagnostic support.
The HLA-B27 (Flow Cytometry) test is a specialized diagnostic assessment designed to detect the presence of the human leukocyte antigen B27 (HLA-B27) gene marker. This antigen is located on the surface of white blood cells and is associated with several autoimmune disorders, including ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and juvenile arthritis.
At Diagnopein Karad, HLA-B27 testing is performed using advanced flow cytometry technology, ensuring higher precision, speed, and reproducibility compared to traditional methods. This powerful diagnostic tool aids clinicians in identifying autoimmune diseases early, enabling timely and effective medical intervention.
Understanding the importance of HLA-B27 testing lies in its role in early detection and clinical decision-making. The presence of the HLA-B27 antigen indicates a genetic predisposition to certain inflammatory and autoimmune conditions, primarily affecting the joints and spinal regions.
This test does not diagnose the disease directly but provides vital insights supporting a physician’s evaluation when symptoms like chronic back pain, stiffness, or joint inflammation are present. Flow cytometry allows rapid and accurate identification of specific cell markers, making this testing method superior in both reliability and turnaround time.
Early screening helps in initiating appropriate treatment protocols, reducing long-term complications, and improving overall patient quality of life. For individuals in Karad and nearby regions, Diagnopein offers trusted HLA-B27 testing with supportive consultation from trained experts.
Testing for HLA-B27 offers several clinical and personal advantages:
Early Diagnosis: Detects predisposition to autoimmune disorders before complications arise.
Accurate and Reliable Results: Flow cytometry ensures precise quantification and minimizes human error.
Faster Turnaround Time: Advanced laboratory automation at Diagnopein delivers rapid reports.
Guides Treatment Decisions: Helps clinicians tailor medication and lifestyle recommendations.
Supports Family Screening: Useful for detecting genetic susceptibility among family members.
Diagnopein’s commitment to diagnostic excellence means patients receive results interpreted by experienced specialists using certified equipment for consistently reliable outcomes.
The flow cytometry technique analyzes thousands of cells per second using laser-based technology to identify antigenic markers on the surface of white blood cells.
Testing Procedure:
A small blood sample is collected from a vein, usually in the arm.
The sample is processed and stained with fluorescent-tagged antibodies specific to the HLA-B27 marker.
Using flow cytometry, cells are passed through a laser beam to detect fluorescence emitted by tagged antibodies.
The system quantifies and reports the percentage of cells expressing HLA-B27 antigen.
Key Parameters Measured:
Presence (+) or absence (–) of HLA-B27 antigen.
Flow cytometric fluorescence intensity (confirming antigen expression).
White blood cell profile for signal accuracy.
Results are interpreted carefully considering the patient’s clinical symptoms, medical history, and imaging findings to build a comprehensive diagnostic picture.
Selecting Diagnopein, Karad ensures your HLA-B27 test is handled with professionalism, accuracy, and compassion.
Our laboratory integrates modern flow cytometry instruments, strict quality protocols, and highly trained technologists who prioritize every sample’s integrity.
Reasons to Choose Diagnopein:
State-of-the-art lab infrastructure with precision diagnostics.
Quick report delivery and transparent test explanation.
Experienced pathologists and customer-focused service.
Convenient sample collection in and around Karad.
Trusted by leading doctors and healthcare providers for autoimmune diagnostics.
Diagnopein stands as a locally trusted diagnostic center committed to quality, accessibility, and patient care.
A negative result suggests the absence of the HLA-B27 marker, lowering the likelihood of associated autoimmune diseases, but it does not entirely rule them out.
A positive result means the HLA-B27 protein is present, which increases the risk of certain autoimmune diseases. However, not everyone with HLA-B27 will develop these conditions, and additional diagnostic tests are typically needed.
Results are generally available within a few days, depending on laboratory processing times.
The test is safe and involves only a standard blood draw, with minor risks of discomfort or bruising at the puncture site.
